Associated Papers
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.
Xiang Y et al.
Current Oncology (toronto, Ont.), 2025
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Yang G et al.
Discover Oncology, 2024
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
Kou T et al.
Cancer Science, 2017
HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
Wang T et al.
Cancer Science, 2017
Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.
Sonobe M et al.
The Journal of Molecular Diagnostics : Jmd, 2006
Select a paper to view details